Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $9.3752W HIGH $23.29
Volume
641.47 K
Value Traded
58.66 M
Short % Float
10.71%
Days to Cover
4.2
+27.49%Week
+7.53%1 Month
-37.47%3 Month
-26.23%6 Month
+82.81%5 Year
+79.04%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.04 B
EPS (TTM)
-3.10
P/E Ratio
-
Ent. Value
613.13 M
Total Shares
85.11 M
Float Shares
75.12 M
Insiders
11.74%
Institutions
82.48%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
MLTX Catalyst Timeline
Dated clinical, regulatory and corporate events for MoonLake Immunotherapeutics
Catalyst Timeline
Dated clinical, regulatory & corporate events for MoonLake Immunotherapeutics
148Total events
12Upcoming
64Tier-1 (high impact)
2021 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲Topline ReadoutSonelokimabClinical Data
IZAR-1 topline results met all clinical endpoints at Week 16
psoriatic arthritissource ↗
◆Enrollment CompleteSonelokimabTrial
IZAR-2 enrollment completion expected in Q3 2026
psoriatic arthritissource ↗
▼Equity OfferingCorporate
Pricing of upsized $200 million public offering of 9,000,000 Class A ordinary shares and pre-funded warrants
▼Equity OfferingCorporate
Proposed public offering of $150 million Class A ordinary shares and pre-funded warrants
▲Full ResultsSonelokimabClinical Data
Week 52 results of VELA-1 trial
hidradenitis suppurativasource ↗
▲Interim AnalysisSonelokimabTrial
Interim Week 24 data from VELA-TEEN trial in adolescent HS
hidradenitis suppurativasource ↗
◆Topline ReadoutSonelokimabClinical Data
Primary endpoint readout of VELA-TEEN trial in adolescent HS
hidradenitis suppurativasource ↗
▲Pre BLA MeetingSonelokimabFDA Meeting
Positive final pre-BLA meeting with FDA on HS program
hidradenitis suppurativasource ↗
▲Oral PresentationSonelokimabPresentation
Week 40 results presented at 2026 AAD Annual Meeting
hidradenitis suppurativasource ↗
▲Full ResultsSonelokimabClinical Data
Week 40 long-term results announced
hidradenitis suppurativasource ↗
▲Topline ReadoutSonelokimabClinical Data
Week 40 topline results announced
hidradenitis suppurativasource ↗
◆R&D DaySLKPresentation
Investor Day to discuss Type B meeting outcome and present new clinical data for SLK
◆R&D DayPresentation
Investor Day with clinical and regulatory updates across multiple indications
◆Interim AnalysisSonelokimabTrial
Interim analysis of continued response beyond week 16 from VELA Phase 3 trials
hidradenitis suppurativa (HS)source ↗
◆Topline ReadoutSonelokimabClinical Data
Data readout from axSpA Phase 2 S-OLARIS program
axial spondyloarthritis (axSpA)source ↗
▲Topline ReadoutSonelokimabClinical Data
Positive topline results from Phase 2 S-OLARIS trial of Sonelokimab in axSpA
axial spondyloarthritissource ↗
▲Fast Track DesignationSonelokimabDesignation
FDA granted Fast Track designation for sonelokimab in PPP
moderate-to-severe palmoplantar pustulosis (PPP)source ↗
▲Type B MeetingSLKFDA Meeting
Positive outcome from Type B meeting with FDA regarding clinical evidence strategy for SLK in HS
hidradenitis suppurativasource ↗
◆Quarterly UpdateCorporate
Lead plaintiff filing deadline for securities class action lawsuit
◆IP Litigation RulingIP / Competition
Lead plaintiff deadline for securities class action lawsuit
◆Type B MeetingSonelokimabFDA Meeting
Type B meeting with FDA scheduled to discuss BLA for HS
hidradenitis suppurativasource ↗
▼Equity OfferingCorporate
Pricing of $75 million underwritten offering of Class A ordinary shares at $10.50 per share
▲Topline ReadoutSonelokimabClinical Data
Phase 2 LEDA trial in PPP shows clinically meaningful and statistically significant benefit
palmoplantar pustulosissource ↗
▲Interim AnalysisSonelokimabTrial
Interim analysis of long-term data from VELA-1 and VELA-2 shows continuous clinical improvement
hidradenitis suppurativasource ↗
▼IP Litigation RulingIP / Competition
Securities class action lawsuit filed against MoonLake Immunotherapeutics
▼Short Report ActivistCorporate
Securities class action lawsuit filed against MoonLake Immunotherapeutics
▼Short Report ActivistCorporate
Securities fraud class action lawsuit filed against MoonLake Immunotherapeutics
◆Oral PresentationSonelokimabPresentation
Presentation of VELA data at key scientific congress in Q4 2025
hidradenitis suppurativasource ↗
▼Primary Endpoint MissedSonelokimabClinical Data
VELA-2 trial failed to achieve statistical significance in week 16 primary endpoint
▼Primary Endpoint MissedClinical Data
VELA-2 trial failed to meet week 16 primary endpoint due to intercurrent events in placebo arm
hidradenitis suppurativasource ↗
▼Topline ReadoutSonelokimabClinical Data
VELA-2 trial topline results: primary endpoint HiSCR75 not met (delta 9% vs placebo)
hidradenitis suppurativasource ↗
▼Topline ReadoutClinical Data
Phase 3 VELA trial failed to meet primary endpoint
hidradenitis suppurativasource ↗
◆Oral PresentationSonelokimabPresentation
Webcast to discuss VELA Phase 3 week 16 results
hidradenitis suppurativasource ↗
◆Topline ReadoutSonelokimabClinical Data
Week 16 topline results of VELA-2 Phase 3 trial of sonelokimab in hidradenitis suppurativa
hidradenitis suppurativasource ↗
▼Primary Endpoint MissedSonelokimabClinical Data
One of two Phase 3 trials missed primary endpoint
hidradenitis suppurativasource ↗
Past FDA Catalysts and PDUFA Decisions
How MLTX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | sonelokimab (SLK) | BLA Submission | BLA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 18%
Micro Cap(rank 119 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sonelokimab Monoclonal antibodyNCT06641076 | Arthritis, Psoriatic | Phase 3 | ACTIVE NOT_RECRUITING | 3,327 | Feb 4, 2027 | ||||||
| Sonelokimab Monoclonal antibodyNCT06768671 | Hidradenitis Suppurativa | NDA/BLA | ACTIVE NOT_RECRUITING | 1,944 | Sep 28, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every MLTX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| sonelokimab Fast Track | psoriatic arthritis | Phase 3 | 2026-08-10 | ACR50: 42.1%; ACR20: 66.5%; MDA: 41.2%; PASI90: 61%Read More | MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial ResultsRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Reich KristianOfficer (Chief Scientific Officer) | Sell | -1,100 2,711,198 held | $20.00 | 07/27/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MLTX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BVF INC/IL | 8 % (-15.8 %) | 311.54 M | 16.00 M |
MLTX Institutional Ownership Trends
MLTX Short Interest
Shares sold short, counted twice a month.
10.71%
Short % of Float
of tradable shares sold short
8.0M
Shares Sold Short
-10.0% vs prior count
4.2 Moderate
Days to Cover
trading days of normal volume to buy every short share back
1.9M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MLTX ranks across every disease it competes in
Competitive Position is a premium feature
See how MLTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMLTX News
MLTX▼ -5.1%on this news
MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results
MoonLake Immunotherapeutics announced positive topline results from the Phase 3 IZAR-1 trial of sonelokimab in biologic-naïve patients with psoriatic arthritis. The trial met all clinical endpoints at Week 16, including a 42.1% ACR50 response. The results indicate significant improvements across multiple disease domains and patient-reported outcomes. The company also reported strong financial results, with sufficient cash runway into mid-2028.
Read more →MLTX▼ -5.7%on this news
MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering
MoonLake Immunotherapeutics has announced the pricing of an upsized public offering of 9 million Class A ordinary shares at $20 each, aiming to raise approximately $200 million. The proceeds will support the development and commercialization of sonelokimab, a treatment for inflammatory diseases. The offering is expected to close on June 25, 2026, pending customary conditions.
Read more →MLTXMoonLake Immunotherapeutics Announces Proposed Public Offering
MoonLake Immunotherapeutics has announced a proposed public offering of $150 million in Class A ordinary shares, with an additional $22.5 million option for underwriters. The funds will support the development and commercialization of sonelokimab, targeting inflammatory diseases. The offering is contingent on market conditions and is detailed in a prospectus filed with the SEC.
Read more →MLTX▲ +15.4%on this newsshared move
MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026
MoonLake Immunotherapeutics announced promising Week 52 results from its Phase 3 VELA trials for sonelokimab in treating moderate-to-severe hidradenitis suppurativa. The data showed a high percentage of patients achieving significant clinical responses and improvements in quality of life. The company plans to submit a Biologics License Application by September 2026 and will host an Investor Day on June 22, 2026, to discuss these findings.
Read more →MLTX▲ +10.4%on this news
MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results
MoonLake Immunotherapeutics announced a positive outcome from its final pre-BLA meeting with the FDA regarding sonelokimab for hidradenitis suppurativa. The FDA accepted MIRA trial data for effectiveness and agreed on the inclusion of VELA-TEEN trial data for adolescents. The BLA submission is planned for September 2026, with a potential commercial launch in late 2027.
Read more →MLTXMoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
MoonLake Immunotherapeutics announced positive results from its Phase 3 VELA trials for sonelokimab in treating moderate-to-severe hidradenitis suppurativa. At Week 40, 62% of patients achieved a HiSCR75 response, with significant improvements in quality of life metrics. The safety profile remained consistent, with no new safety signals detected. Detailed results will be presented at the 2026 AAD Annual Meeting.
Read more →MLTXMoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results
MoonLake Immunotherapeutics announced positive topline results from its Phase 2 clinical trial of sonelokimab in patients with axial spondyloarthritis. The trial demonstrated that 81% of participants achieved a significant improvement according to the ASAS40 response criteria at Week 12. The results indicate that sonelokimab has a rapid onset of action and effectively addresses inflammation in affected tissues. Additionally, the company's financial results from 2025 show sufficient funds to cover operations until mid-2027, supporting further developments in their pipeline that includes trials for other inflammatory diseases.
Read more →MLTXMoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day
MoonLake Immunotherapeutics has received FDA Fast Track designation for sonelokimab to treat moderate-to-severe palmoplantar pustulosis (PPP). This designation aims to expedite the drug's development and review process, reflecting the serious nature of PPP and the lack of approved treatments. The company will also hold an Investor Day on February 23, 2026, to provide updates on various clinical programs.
Read more →MLTX▲ +27%on this news· ran to +64% by day 1
MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day
MoonLake Immunotherapeutics announced a positive outcome from its Type B meeting with the U.S. FDA, indicating that it can submit a Biologics License Application (BLA) for sonelokimab (SLK) without additional clinical trials. The FDA recognized the substantial evidence of effectiveness based on results from the VELA and MIRA trials for the treatment of hidradenitis suppurativa (HS). The meeting provided clarity for MoonLake's regulatory pathway and potential for further development of SLK for additional indications. An Investor Day is planned to discuss these outcomes and present new clinical data.
Read more →MLTXMoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering
MoonLake Immunotherapeutics has announced the pricing of an underwritten offering of 7,142,857 Class A ordinary shares at $10.50 each, aiming to raise approximately $75 million. The proceeds will support the development of sonelokimab and general corporate purposes. The offering is expected to close on November 6, 2025, pending customary closing conditions.
Read more →MLTXMoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab
MoonLake Immunotherapeutics reported its Q3 2025 financial results, highlighting a robust cash position of $380.5 million. The company shared promising data from its clinical trials of sonelokimab, particularly in the Phase 2 LEDA trial for palmoplantar pustulosis, showing significant clinical benefits. A Phase 3 trial is expected to commence in Q3 2026, with an FDA meeting scheduled for December 2025 to discuss the BLA submission.
Read more →MLTX▼ -89.9%on this newsshared move
MoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3 hidradenitis suppurativa program with the Nanobody® sonelokimab
MoonLake Immunotherapeutics reported positive week 16 results from its Phase 3 VELA trials for sonelokimab in treating moderate-to-severe hidradenitis suppurativa. The trials demonstrated statistically significant improvements in key endpoints, including HiSCR75 response rates and patient-reported outcomes. Despite a higher-than-expected placebo response in one trial, the overall safety profile remains favorable. The company plans to discuss these results with regulators as they move towards a potential Biologics License Application.
Read more →MLTXMoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics reported strong financial results for Q2 2025, highlighting a cash position of $425.1 million and an earlier-than-expected interim readout from the Phase 2 LEDA trial. The company narrowed its guidance for the Phase 3 VELA program's primary endpoint readout to September. Upcoming milestones include data presentation at a key scientific congress in Q4 2025.
Read more →MLTXMoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update
Read more →MLTXMoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29
MoonLake Immunotherapeutics will host a virtual Capital Markets Day on April 29, 2025, to discuss recent financial and clinical advancements. The event will feature insights from key executives and cover the company's non-dilutive financing agreement, updates on the VELA program, and interim results from the LEDA study. A Q&A session will follow the presentations.
Read more →MLTXMoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates
MoonLake Immunotherapeutics announced a significant agreement with Hercules Capital for up to $500 million in non-dilutive financing. This funding will support the advancement of sonelokimab, a novel treatment for inflammatory diseases. The company plans to provide important clinical updates during a Capital Markets Update on April 29, 2025, including pivotal data readouts for ongoing trials.
Read more →MLTXMoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
Read more →MLTXMoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab
MoonLake Immunotherapeutics has initiated three new clinical trials for sonelokimab, targeting adolescent hidradenitis suppurativa, palmoplantar pustulosis, and axial spondyloarthritis. This expansion increases the total number of clinical trials to ten, with plans to enroll over 3,000 patients. The trials aim to address significant unmet medical needs in dermatology and rheumatology.
Read more →MLTXMoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis
MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis
Read more →MLTXMoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update
Read more →About MoonLake Immunotherapeutics
HeadquartersDORFSTRASSE 29, ZUG, V8, 6300
BIOPHARMAWATCH ELITE PLUS
Trade the next MLTX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime